Decreased anti-Saccharomyces cerevisiae antibody titer by mesalazine in patients with Crohn's disease

Decreased anti-Saccharomyces cerevisiae antibody titer by mesalazine in patients with Crohn's disease
复制标题

DOI:
10.1046/j.1440-1746.2000.02357.x
复制
发表时间:
2000-12-01
影响因子:
4.1
通讯作者:
Kuroki, T
Kuroki, T
中科院分区:
医学3区
文献类型:
--
作者:
Oshitani, N;Hato, F;Kuroki, T

文献摘要

被引文献

相似文献

背景:酿酒酵母可能参与克罗恩病的病理生理过程。方法和结果:采用ELISA法检测19例溃疡性结肠炎患者、18例克罗恩病患者和7例健康对照者血清中抗酿酒酵母抗体(ASCA)水平。溃疡性结肠炎患者和克罗恩病患者的ASCA水平显著高于对照组,克罗恩病患者的ASCA水平显著高于溃疡性结肠炎患者。年龄、性别、疾病活动度、疾病程度和小肠受累:每一项都不影响ASCA水平。对克罗恩病患者使用元素或聚合物饮食疗法以及对炎症性肠病患者使用皮质类固醇也不影响ASCA水平。服用5-氨基水杨酸的克罗恩病患者的ASCA滴度明显低于未服用的患者,尽管这两组患者的血清IgG水平没有差异,这可能意味着5-氨基水杨酸在肠道水平抑制IgG的产生。炎症性肠病患者血清ASCA滴度升高的发现表明,酿酒酵母可能在炎症性肠病的病理生理学中发挥作用。这个条件。(C); 2000 Blackwell Science Asia Pty Ltd.
Background: Saccharomyces cerevisiae may contribute to the pathophysiology of Crohn's disease. We determined serum anti-Saccharomyces cerevisiae antibody (ASCA) levels in patients with inflammatory bowel disease.Methods and Results: Immunoglobulin G (IgG) ASCA was measured by using an ELISA in serum samples from 19 patients with ulcerative colitis, 18 patients with Crohn's disease and 7 healthy controls. The ASCA level was significantly higher in patients with ulcerative colitis and patients with Crohn's disease than in controls, and was significantly higher in patients with Crohn's disease compared with patients with ulcerative colitis. Age, gender, disease activity, extent of disease and small bowel involvement: each did not affect ASCA levels. The use of elemental or polymeric diet therapy for Crohn's disease and administration of corticosteroids to patients with inflammatory bowel disease also did not affect ASCA levels. The ASCA titer was significantly lower in patients with Crohn's disease taking mesalazine than in those not taking it, although, serum IgG levels did not differ between these two groups, which might imply a suppression of IgG production by mesalazine at the intestinal level.Conclusions: The finding of increased serum ASCA titers in patients with inflammatory bowel disease suggests that Saccharomyces cerevisiae may play a role in the pathophysiology of this condition. (C); 2000 Blackwell Science Asia Pty Ltd.